Homology Medicines (LTS:0T6G) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Change In Receivables?

Homology Medicines's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Homology Medicines's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Homology Medicines's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Homology Medicines's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Homology Medicines's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Homology Medicines's liquidation value for the three months ended in Dec. 2023 was $71.08 Mil.

Homology Medicines Change In Receivables Historical Data

The historical data trend for Homology Medicines's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Change In Receivables Chart

Homology Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Homology Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Homology Medicines Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Homology Medicines (LTS:0T6G) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Homology Medicines's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Homology Medicines's accounts receivable are only considered to be worth 75% of book value:

Homology Medicines's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	82.653	-	11.573	+	0.75 * 0	+	0.5 * 0
=	71.08

Homology Medicines Change In Receivables Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (LTS:0T6G) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (LTS:0T6G) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

FIXX:USA 35H:Germany

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (LTS:0T6G) Headlines

No Headlines